Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
immediate release guanfacine · 1 trial · 1 indication
QTcNi is the QT interval using a subject-specific correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate (e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation.
QTcNi is the QT interval using a subject-specific correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate (e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation.
QTcF is the QT interval using Fridericia's correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate (e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation.
QTcF is the QT interval using Fridericia's correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate (e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation.
QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate (e.g., the faster the heart rate, the shorter the QT interval).
QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate (e.g., the faster the heart rate, the shorter the QT interval).
| Arm | Type | Description |
|---|---|---|
| Immediate-release Guanfacine HCl | EXPERIMENTAL | - |
| Moxifloxacin HCl | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| immediate release guanfacine hydrochloride | DRUG | Subjects will receive 2x2mg immediate-release guanfacine on day 1. Subjects will receive 4x2mg immediate-release guanfacine on day 6. |
| moxifloxacin | DRUG | Subjects will receive 400mg of moxifloxacin on day 1. Subjects will receive 400mg of moxifloxacin on day 6. |
| Placebo | DRUG | Subjects will receive placebo on Day 1. Subjects will receive placebo on Day 6. |
Inclusion Criteria: * Healthy Normal Subjects
Immediate release guanfacine is a small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development. The only completed trial evaluated its effects on the electrocardiogram, specifically the QTc interval, in healthy adult participants in the United States.
Immediate release guanfacine is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company conducted a Phase 1 study of the drug in healthy volunteers in the United States.
Immediate release guanfacine is in Phase 1 clinical development. It is an investigational drug and has not been approved. One Phase 1 trial, NCT00672984, has been completed, and no active trials are currently listed.
Immediate release guanfacine has one completed clinical trial, NCT00672984, titled "Guanfacine Immediate-release Electrocardiogram Results (QTc) Study." This Phase 1, randomized, double-blind, placebo-controlled study enrolled 83 healthy volunteers in the United States.
Immediate release guanfacine is a formulation of guanfacine, a small molecule. The clinical trial NCT00672984 specifically studied the immediate-release version of guanfacine to assess its effect on the QTc interval in healthy volunteers.